Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung01: datopotamab deruxtecan versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer
jRCT2071200104Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Datopotamab deruxtecan with Docetaxel (2 arms). Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
datopotamab deruxtecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071200104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200104.